EDAP Earnings Prediction
The chart below shows how EDAP performed 10 days before and after its earnings report, based on data from the past quarters. Typically, EDAP sees a +9.28% change in stock price 10 days leading up to the earnings, and a -0.22% change 10 days following the report. On the earnings day itself, the stock moves by -2.58%. This data can give you a slight idea of what to expect for the next quarter's release.
EDAP Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
13.10M
11.60%
-17.05%
Gross Margin
39.35%
10.94%
4.99%
Operating Margin
-44.53%
-5.86%
14.38%
Net Margin
-48.85%
45.30%
25.80%
EPS
-0.17
-54.55%
6.25%
No Data Available
EDAP Earnings Analysis
EDAP TMS SA Corporation (EDAP.O) Earnings Conference Call
Positive
Worldwide Revenue Growth: Total world wide revenue in U.S. dollars of $14.4 million, representing currency-adjusted growth of 11.6% on a year-over-year basis.
Focal One Revenue Surge: Core Focal One HIFU business continues to experience strong growth with a 48.2% year-over-year increase in revenues, reflecting continued adoption of Focal One in the global urology community.
Focal One System Placements: We placed three Focal One systems in the third quarter, which included a system placement, Virginia Commonwealth University, as well as placements in Italy and Spain.
U.S. Procedure Growth: During the quarter, U.S. procedures grew 34% on a year-over-year basis, which reflects continued adoption by urologists who see Focal One as an important treatment option for delivering targeted focal therapy in earlier-stage prostate cancer patients.
HIFU Revenue Growth: Total revenue in the HIFU business for the third quarter of 2024 was €4.5 million as compared to €3 million for the third quarter of 2023, which represents growth of 48.2% year-over-year.
Negative
Worldwide Revenue Growth: Total world wide revenue in U.S. dollars of $14.4 million, representing currency-adjusted growth of 11.6% on a year-over-year basis.
Operating Expenses Increase: Operating expenses were €11 million for the third quarter compared to €9.7 million for the same period in 2023.
Operating Loss Comparison: Operating loss for the third quarter of 2024 was €5.8 million, which was relatively flat compared to an operating loss of €5.6 million in the third quarter of 2023.
Quarterly Net Loss Comparison: Net loss for the third quarter of 2024 was €6.4 million or €0.17 per diluted share, as compared to net loss of €3.9 million or €0.11 per diluted share in the year ago period.
Inventory Comparison Q3 2024: Ending inventory was €21 million in the third quarter of 2024 as compared to €15.1 million at the end of the fourth quarter in 2023.
EDAP FAQs
How does EDAP typically perform around its earnings report dates?
Is EDAP TMS S.A. (EDAP) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
EDAP Earning Call Sentiment
EDAP TMS S.A. (EDAP) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
EDAP.O
-3.63%Positive
The earnings call summary presents a mixed picture. Financial performance shows growth in revenue and gross profit, but increased net loss and cash decrease are concerning. Product development and market strategy are positive, with new trials and increased adoption. However, competitive pressures and regulatory challenges are highlighted. The Q&A section indicates positive momentum but lacks clarity on certain aspects. No shareholder return plan is a negative factor. Overall, these mixed signals suggest a neutral stock price movement over the next two weeks.
